ESSA Competitors

Delisted . USA . 
Stock . ESSA Pharma
EPIXDelisted Stock  USD 0.20  0.00  0.00%   
ESSA Pharma competes with COSCIENS Biopharma, CervoMed, Biora Therapeutics, and Frequency Therapeutics; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing ESSA Pharma competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of ESSA Pharma to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

ESSA Pharma vs Turnstone Biologics Correlation

Very good diversification

The correlation between ESSA Pharma and TSBX is -0.38 (i.e., Very good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding ESSA Pharma and TSBX in the same portfolio, assuming nothing else is changed.

Moving together with ESSA Stock

  0.87TRNR Interactive StrengthPairCorr
  0.88APVO Aptevo TherapeuticsPairCorr

Moving against ESSA Stock

  0.86NTZ Natuzzi SpAPairCorr
  0.84CYD China Yuchai Interna Earnings Call This WeekPairCorr
  0.83EMMA Emmaus Life SciencesPairCorr
  0.81TOGOF TomaGoldPairCorr
  0.81CGECF Cogeco IncPairCorr
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.200.200.20
Details
Intrinsic
Valuation
LowRealHigh
0.190.190.22
Details

ESSA Pharma Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between ESSA Pharma and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of ESSA and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of ESSA Pharma does not affect the price movement of the other competitor.

High positive correlations

CRVO
+ 0.85
TNFA
CSCI
+ 0.41
TNFA
SCPX
+ 0.39
CHRO
SCPX
+ 0.33
CRVO
SCPX
+ 0.29
TNFA
SCPX
+ 0.29
CSCI
  

High negative correlations

TSBX
- 0.55
SCPX
TSBX
- 0.47
CHRO
KRRO
- 0.47
CRVO
TSBX
- 0.33
TNFA
TSBX
- 0.31
CRVO
KRRO
- 0.2
TNFA

Risk-Adjusted Indicators

There is a big difference between ESSA Stock performing well and ESSA Pharma Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze ESSA Pharma's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
APGN  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
TNFA  8.70 (0.58) 0.00  0.28  0.00 
 0.00 
 17.75 
(20.86)
 79.44 
CSCI  6.78  0.24  0.01  0.54  11.10 
(8.88)
 27.11 
(28.04)
 94.83 
CRVO  3.66 (0.57) 0.00 (0.85) 0.00 
 0.00 
 6.84 
(7.29)
 22.71 
CHRO  5.31  0.37  0.06  1.99  5.79 
(7.41)
 10.27 
(10.69)
 68.90 
SCPX  251.87  132.58  2.04  25.59  47.89 
(621.25)
 733.33 
(89.29)
 4,498 
BIOR  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
KRRO  5.04 (0.52) 0.00 (0.05) 0.00 
 0.00 
 10.98 
(6.05)
 79.31 
TSBX  2.57  0.19  0.03  2.41  3.05 
(4.24)
 6.06 
(6.06)
 21.24 

ESSA Pharma Competitive Analysis

The better you understand ESSA Pharma competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, ESSA Pharma's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across ESSA Pharma's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
EPIX TNFA CSCI CRVO CHRO SCPX BIOR KRRO TSBX
 0.00 
 0.20 
ESSA
 9.72 
 5.20 
TNF
 9.57 
 2.06 
COSCIENS
 3.81 
 4.54 
CervoMed
 8.20 
 16.50 
Chromocell
 55.56 
 0.0004 
Scorpius
 0.00 
 0.22 
Biora
 2.78 
 11.48 
Frequency
 0.00 
 0.36 
Turnstone
Market Volatility
(90 Days Market Risk)
Very steady
Very steady
Abnormally volatile
Slightly risky
Very steady
Out of control
Very steady
Somewhat reliable
Very steady
Market Performance
(90 Days Performance)
Weakest
Weakest
Mild
Weakest
Weakest
Solid
Weakest
Solid
Weakest
Odds of Financial Distress
(Probability Of Bankruptcy)
Hazard
Hazard
Average
Small
Hazard
High
Risky
High
Hazard
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Under Valued
Over Valued
Over Valued
Over Valued
Under Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Strong Buy
Not Available
Strong Buy
Not Available
Strong Buy
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Not Rated
Strong Sell
Hold
Not Rated
Strong Sell
Strong Sell
Hold
Not Rated
Current Ratio
43.43
N/A
N/A
N/A
N/A
N/A
1.69
N/A
N/A
Net Asset
128.11 M
21.42 M
35.07 M
43.08 M
1.37 M
39.18 M
31.21 M
226.24 M
40.14 M
Profit Margin
N/A
N/A
-2.0
N/A
N/A
N/A
N/A
N/A
N/A
EBITDA
(28.45 M)
(23.36 M)
(13.49 M)
(18.23 M)
(7.57 M)
(26.22 M)
(114.05 M)
(88.34 M)
(68.97 M)
Current Valuation
(99.33 M)
5.9 M
1.31 M
16.38 M
91.42 M
19.97 M
38.44 M
57.38 M
(8.06 M)
Price To Book
0.0944
1.26
1.17
1.68
4.11
0.1
N/A
1.06
0.56
Operating Margin
N/A
N/A
-0.86
-24.94
N/A
-25.38
N/A
-17.65
N/A
Retained Earnings
(208 M)
(129.14 M)
(12.11 M)
(70.73 M)
(21.47 M)
(287.18 M)
(950.96 M)
(266.59 M)
(247.59 M)
Current Asset
10.02 M
N/A
N/A
N/A
317 K
N/A
667 K
N/A
N/A
Beta
1.53
2.28
1.85
-6.23
N/A
1.42
1.28
2.44
1.37
Number Of Employees
35
6
40
15
4
90
58
87
14
Shares Outstanding
47.31 M
1.85 M
3.18 M
9.25 M
6.6 M
61.14 M
4.52 M
9.42 M
23.14 M
Cash Flow From Operations
(22.72 M)
(8.98 M)
(14.57 M)
(16.53 M)
(5.79 M)
(26.01 M)
(48.5 M)
(60.07 M)
(67.44 M)
Annual Yield
0.88
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Debt
329.26 K
10.58 K
2.31 M
3.88 M
2.19 M
28.55 M
47.43 M
44.77 M
1.19 M
Return On Equity
-0.21
-1.15
-1.13
-0.71
N/A
-5.16
N/A
-0.63
-1.27
Z Score
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Return On Asset
-0.15
-0.24
-0.17
-0.43
-1.89
-0.57
-1.25
-0.29
-0.58
Number Of Shares Shorted
1.35 M
5.72 M
9.91 K
234.76 K
76.91 K
278.26 K
258.12 K
1.14 M
281.36 K
Book Value Per Share
2.45
17.47
2.24
2.81
-6.78
-0.041
-36.43
10.54
0.64
Current Liabilities
3.63 M
N/A
N/A
N/A
166 K
N/A
3.01 M
N/A
N/A
Total Asset
128.11 M
21.42 M
35.07 M
43.08 M
1.37 M
39.18 M
31.21 M
226.24 M
40.14 M
Debt To Equity
0.001
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Short Ratio
0.39
0.07
1.67
3.02
0.88
0.56
2.37
3.91
1.27
Target Price
1.74
N/A
N/A
22.43
8.5
5.0
34.0
19.33
1.0
Shares Owned By Institutions
73.7
0.29
8.93
24.1
13.6
N/A
36.0
93.42
51.49
Market Capitalization
9.52 M
6.48 M
8.64 M
43.67 M
8.9 M
55.03 K
1.86 M
105.19 M
8.21 M
Price To Earning
-1.12
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Price To Sales
N/A
N/A
0.92
7.09
N/A
0.0228
1.49
14.27
2.13
Net Income
(28.54 M)
(23.36 M)
(15.31 M)
(16.29 M)
(7.96 M)
(34.33 T)
(124.11 M)
(83.58 M)
(70.84 M)
Earnings Per Share
-0.57
-202.0
-6.54
-2.9
-12.0
19.11
0.36
-9.42
-2.04
Shares Owned By Insiders
5.61
0.009
1.48
32.16
53.88
0.057
0.1
6.58
7.69
Revenue
N/A
N/A
13.78 M
9.74 M
N/A
6.24 M
4 K
2.27 M
N/A
Working Capital
124.26 M
2.71 M
16.76 M
39.2 M
(2.71 M)
(21.03 M)
(43.9 M)
116.57 M
26.02 M
Cash And Equivalents
174.6 M
N/A
N/A
N/A
N/A
N/A
37.06 M
N/A
N/A
Cash Per Share
3.96
N/A
N/A
N/A
N/A
N/A
0.19
N/A
N/A
Gross Profit
N/A
N/A
4.42 M
(16.91 M)
272.31 K
(12.39 M)
1.25 M
46 K
(55.63 M)
Day Typical Price
0.2
6.11
2.06
4.65
15.93
4.0E-4
0.22
11.68
0.36
Accumulation Distribution
0.0952
0.53
N/A
3684.19
0.22
N/A
N/A
16242.07
N/A
Market Facilitation Index
0.02
4.74
N/A
0.0
3.77
N/A
N/A
0.0
N/A
Daily Balance Of Power
N/A
(0.12)
9.2 T
(0.49)
0.3316
0
0.0
0.3039
0.0
Period Momentum Indicator
N/A
(0.56)
0.18
(0.18)
1.25
(0.0005)
N/A
0.31
N/A
Rate Of Daily Change
1.0
0.9
1.1
0.96
1.08
0.44
1.0
1.03
1.0
Day Median Price
0.2
6.57
2.06
4.71
15.65
4.0E-4
0.22
11.78
0.36
Price Action Indicator
N/A
(1.65)
0.09
(0.25)
1.48
(0.0003)
N/A
(0.14)
N/A
Coefficient Of Variation
(550.57)
(1,970)
5173.95
(885.24)
2216.27
446.58
N/A
(3,950)
1864.69
Mean Deviation
4.85
8.7
6.78
3.66
5.31
251.87
N/A
5.04
2.57
Jensen Alpha
(2.06)
(0.58)
0.2411
(0.57)
0.3734
132.58
N/A
(0.52)
0.1873
Total Risk Alpha
(2.70)
(1.39)
(0.50)
(0.80)
(0.09)
100.69
N/A
(0.89)
(0.01)
Sortino Ratio
N/A
N/A
0.0148
N/A
0.0551
2.04
N/A
N/A
0.0289
Downside Variance
N/A
N/A
218.99
N/A
37.71
4247.85
N/A
N/A
26.08
Standard Deviation
11.4
13.16
14.06
4.75
8.68
593.12
N/A
11.09
3.74
Kurtosis
25.24
4.59
7.08
0.9483
12.37
42.61
N/A
40.58
1.62
Potential Upside
5.0
17.75
27.11
6.84
10.27
733.33
N/A
10.98
6.06
Treynor Ratio
3.92
0.2841
0.5439
(0.85)
1.99
25.59
N/A
(0.05)
2.41
Maximum Drawdown
75.44
79.44
94.83
22.71
68.9
4498.0
N/A
79.31
21.24
Variance
129.99
173.1
197.78
22.59
75.33
351787.77
N/A
122.98
14.0
Market Risk Adjusted Performance
3.93
0.2941
0.5539
(0.84)
2.0
25.6
N/A
(0.04)
2.42
Risk Adjusted Performance
(0.14)
(0.03)
0.0248
(0.08)
0.045
0.188
N/A
(0.01)
0.0505
Skewness
(4.87)
1.32
1.33
0.4765
2.35
6.15
N/A
(5.59)
0.1454
Semi Deviation
N/A
N/A
11.1
N/A
5.79
47.89
N/A
N/A
3.05
Information Ratio
(0.19)
(0.05)
0.0156
(0.12)
0.039
0.2238
N/A
(0.03)
0.0395
Value At Risk
(5.00)
(20.86)
(28.04)
(7.29)
(10.69)
(89.29)
N/A
(6.05)
(6.06)
Expected Short fall
N/A
N/A
(8.88)
N/A
(7.41)
(621.25)
N/A
N/A
(4.24)
Downside Deviation
N/A
N/A
14.8
N/A
6.14
65.18
N/A
N/A
5.11
Semi Variance
N/A
N/A
123.26
N/A
33.54
2293.72
N/A
N/A
9.28

ESSA Pharma Competition Performance Charts

Five steps to successful analysis of ESSA Pharma Competition

ESSA Pharma's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by ESSA Pharma in relation to its competition. ESSA Pharma's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of ESSA Pharma in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact ESSA Pharma's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to ESSA Pharma, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your ESSA Pharma position

In addition to having ESSA Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run USA Crypto Assets Thematic Idea Now

USA Crypto Assets
USA Crypto Assets Theme
An experimental p2p digital currency that is accepted by many vendors in null. The USA Crypto Assets theme has 0 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize USA Crypto Assets Theme or any other thematic opportunities.
View All  Next Launch
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.

Other Consideration for investing in ESSA Stock

If you are still planning to invest in ESSA Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ESSA Pharma's history and understand the potential risks before investing.
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Global Correlations
Find global opportunities by holding instruments from different markets
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY